Back to drug

The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

X.h

Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

Publications

Dunogué B, Pagnoux C, Guillevin L

Churg-strauss syndrome: clinical symptoms, complementary investigations, prognosis and outcome, and treatment.

Seminars in respiratory and critical care medicine. 2011;32(3):298-309

Wechsler ME, Pauwels R, Drazen JM

Leukotriene modifiers and Churg-Strauss syndrome: adverse effect or response to corticosteroid withdrawal?

Drug safety. 1999;21(4):241-51

Green RL, Vayonis AG

Churg-Strauss syndrome after zafirlukast in two patients not receiving systemic steroid treatment.

Lancet (London, England). 1999;353(9154):725-6

Knoell DL, Lucas J, Allen JN

Churg-Strauss syndrome associated with zafirlukast.

Chest. 1998;114(1):332-4

Holloway J, Ferriss J, Groff J, Craig TJ, Klinek M

Churg-Strauss syndrome associated with zafirlukast.

The Journal of the American Osteopathic Association. 1998;98(5):275-8